Skip main navigation

Home > Search Results

Main contents starts here

Search Results

141 - 160 of about 208

Total 208 documents found.

  •  
  • Takeda Internet Site: Terms and Conditions of Use
  • This Internet site is owned and operated by Takeda Pharmaceutical Company Limited ("Takeda"). By using this Internet site, you are representing your consent to the following terms and conditions.
  • Out Licensing
  • Takeda may also conduct the development and sales of our original compounds with expertized partners with excellent know-how to deliver them to the world as early as possible.
  • Approval of Actos® Orally Disintegrating Tablets in Japan January 18, 2010
  • January 18, Osaka, Japan – Takeda Pharmaceutical Company Limited (“Takeda”) today announced it has received approval from the Japanese Ministry of Health, Labour and Welfare for Actos® OD tablets 15 and 30 (pioglitazone HCI; Actos OD tablets), for the treatment of type 2 diabetes. Takeda is the originator of Actos which helps reduce insulin resistance, which is one of the major causes of type 2 diabetes. In Japan, Actos tablets were approved and launched in 1999, and a New Drug Application for the new OD tablet formulation was submitted in September 2008.
  • Consolidated ResultsConsolidated Results First Quarter of Fiscal 2009 Hiroshi Takahara Corporate Officer, General Manager Finance & Accounting Department FY08 1Q FY09 1Q billions of yen billions of yen billions of yen Net Sales 396.9 379.0 - 17.9 - 4.5% Year-on-year change Consolidated Results Summary Net Sales 396.9 379.0 17.9 4.5% Gross Profit 318.3 307.6 - 10.6 - 3.3% SG&A Expenses 110.6 117.1 + 6.5 + 5.9% Intangible Fixed Assets & Goodwill Amortization Costs 15.1 22.3 + 7.2 + 48.0% R&D Expenses 234.8 64.9 - 170.0 - 72.4% In-process R&D Expenses 166.2 - 166.2 Operating Income - 27.2 125.6 + 152.8 Excluding the Effect of Extraordinary Factors 154.1 148.0 - 6.2 - 4.0% Net Income 2.5 112.6 + 110.1 Excluding the Effect of Extraordinary Income/Loss & Other Extraordinary Factors 105.3 128.1 + 22.8 + 21.6% E P S * 127.25 yen 162.26 yen + 35.01 yen + 27.5% * Excluding the effects of extraordinary income/loss and other extraordinary factors 1 Year-on-year Increase Currency Translation Effect (Year-on-year Increase
  • Consolidated ResultsConsolidated Results Third Quarter of Fiscal 2009 Hiroshi Takahara Corporate Officer General Manager Finance & Accounting Department FY08 Apr-Dec FY09 Apr-Dec billions of yen billions of yen billions of yen Year-on-year change Consolidated Results Summary Net Sales 1,202.8 1,127.9 - 74.8 - 6.2% Gross Profit 981.5 913.3 - 68.2 - 6.9% SG&A Expenses 364.0 347.8 - 16.2 - 4.4% Excluding Intangible Fixed Assets & Goodw ill Amortization Costs 302.0 284.7 - 17.3 - 5.7% R&D Expenses 377.6 209.3 - 168.3 - 44.6% Excluding IPR&D expenses 214.1 209.3 - 4.8 - 2.2% Operating Income 239 9 356 2 + 116 3 + 48 5%Operating Income 239.9 356.2 + 116.3 + 48.5% Excluding Extraordinary Factors 465.6 419.5 - 46.1 - 9.9% Net Income 168.6 259.1 + 90.6 + 53.7% Excluding Extraordinary Income/Loss & Other Extraordinary Factors 302.0 303.2 + 1.2 + 0.4% E P S * 370.71 yen 384.04 yen + 13.33 yen + 3.6% * Excluding Extraordinary Income/Loss & Other Extraordinary Factors 1 Year-on-year Increase Currency Translation Effect (
  • Annual Report 2009 Based on Takeda-ism Relationship with Our Stakeholders CSR Data Book Annual Report 2009 1 CSR Data Book 2 12 14 16 18 20 22 24 26 Relationship with Society Relationship with Environment Relationship with Suppliers Relationship with Employees 8 Quality Assurance System 56 Stakeholders' Voices Employees Who Embody the Takeda-ism Ideals 28 30 32 33 34 36 37 38 40 42 43 44 46 48 50 52 54 4 Scope of Reporting Participating in the United Nations Global Compact Annual Report 2009 - Takeda Pharmaceutical Company Limited Table of Contents Editorial Policy Basic Policy on CSR / CSR Promotion Framework / CSR Activities in Fiscal 2009 Feature Feature: Access to Healthcare in Asia (Activities in Asia) Takeda's Corporate Citizenship Activities Activities in the U.S. Activities in France and Germany Activities in Italy and the UK Activities in Japan and Taiwan Activities in the Philippines and Thailand Other Activities Feature: Supply Chain Management Basic Purchasing Policy / Green Procurement and CSR P
  • 95 Review of Operations and Financial Condition Takeda Pharmaceutical Company Limited and Subsidiaries Year ended March 31, 2009 (Fiscal 2008) Overview of Results The environment facing the pharmaceutical industry is becoming challenging, due to U.S. government policy that public medical insurance costs be reduced in the U.S., which is the largest market in the world, and in addition to that, due to initiatives in Japan and Europe to promote generic use, as well as the worldwide implementation of a stricter approval process for new drugs. Furthermore, the pharmaceutical industry has been facing difficulty in creating breakthrough novel drugs due to the difficulties of translating new innovations to products in the marketplace. Takeda's response to these global challenges is to channel all its energy on efforts aimed at sustainable growth towards "world-class pharmaceutical company." Initiatives and strategies undertaken in last fiscal year included large-scale acquisition and reorganization. Firstly, TAP Pha
  • 38 We provide superb pharmaceutical productsthe ultimate goal of "Takeda-ism"to global medical professions and patients For prostate cancer, breast cancer and endometriosis For peptic ulcers A reliable partner for consumers in the age of self-medication Consumer Healthcare Drugs & Quasi-Drugs (Consumer Healthcare Business) Benza Block S Banze Block L Banza Block IP In the consumer healthcare business, Takeda sells over-the-counter (OTC) drugs as one element of its pharmaceuticals business. Takeda believes OTC drugs will become an increasingly important product category in view of the "age of self-medication" to come. In fiscal 2008, consumer healthcare business sales increased 4.1 percent to 64.4 billion. The regulatory environment changed in June 2009 with the enactment of the first amendments to Japan's Pharmaceutical Affairs Law in about 50 years. For OTC drugs, in addition to supplying quality products that are safe and effective, companies must meet stricter requirements for providing consumers with dru
  • 34 Intellectual property activities are vital to our ability to contribute to society as a provider of outstanding pharmaceutical products The Four Central Themes of Intellectual Property Activities Well over 10 years is needed for the R&D process that extends from drug discovery to final approval of a new pharmaceutical product. Furthermore, despite the enormous expenditures required to develop drugs, only a very small percentage of compounds reach the market. Drugs that are approved for sale in most cases are protected by a substance patent, which covers the drug's active ingredient. This patent is critical to the R&D process. Prospects for obtaining a patent can even be the deciding factor in whether or not to proceed with the development of a product. This is why all pharmaceutical companies place so much importance on the effective use of intellectual property, including basic patents. Without sufficient intellectual property, companies would be unable to generate the earnings needed for drug developmen
  • 66 Third Party Opinion Yoshito Nakamura Professor, Toyo University Faculty of Business Administration, Certified Public Accountant Head of the Supporting Organization of J.O.C.V. Head of the Kawasaki City Council of Social Welfare Committee Member for the Office Security Mark Certification System, New Office Promotion Association Member of the Evaluation Committee for Independent Administrative Institutions, Japanese Ministry of Defense This third party opinion regarding Takeda Pharmaceutical Company Limited ("the Company") has been tendered after reviewing the Company's Annual Report 2009 and CSR Data Book ("the Data Book"), and interviewing those responsible for the creation of the Data Book. As a company aiming to become a "World-Class Pharmaceutical Company," Takeda has joined the UN Global Compact from this year, and is currently working to implement the rigorous requirements of global society as encapsulated in the Compact's 10 principles on human rights, labor, the environment and other areas. It is m
  • Initiation of Pivotal Phase III Study with Catena®/Sovrima® (Idebenone) in Duchenne Muscular Dystrophy September 3, 2009
  • Liestal, Switzerland (September 2, 2009) and Osaka, Japan (September 3,2009) – Santhera Pharmaceuticals (SIX: SANN, “Santhera”), a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) announced today that Santhera has initiated the pivotal Phase III study with Catena®/Sovrima® (INN: Idebenone) for the treatment of Duchenne Muscular Dystrophy, one of the most common and devastating types of muscular degeneration. The 12-month DELOS study will enroll up to 240 patients in 25 centers in Europe and North America. The start of patient enrollment into this Phase III study has triggered a milestone payment of EUR 5 million from Takeda, marketing partner in the European Union and Switzerland, already received by Santhera.
  • CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer July 7, 2009
  • Numazu and Osaka, Japan and Cambridge, MA, USA – July 7, 2009 --- CanBas Co., Ltd. (Numazu, Shizuoka, “CanBas”) and Takeda Pharmaceutical Company Limited (Osaka, “Takeda”) together with Takeda’s wholly-owned subsidiary Millennium: The Takeda Oncology Company (Cambridge, MA, “Millennium”) today announced the advancement of CBP501 into Phase II clinical trials for the treatment of patients with non-small cell lung cancer (NSCLC). Current pre-clinical data suggest that CBP501 has the potential to induce cancer cell death through a mechanism of action that blocks the ability of cancer cells to transition through the cell cycle. Data from a previous Phase I study indicate that CBP501 may enhance anti-cancer cytotoxic activity when combined with selected chemotherapeutic drugs.
  • Lancet Publishes Phase 3 Clinical Data on Basen® April 23, 2009
  • April 23, 2009, Osaka, Japan --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced the publication of an article describing the Phase 3 clinical data of Basen® (generic name: voglibose) —drug for treatment for postprandial hyperglycemia in diabetes mellitus in one of the world’s most prestigious medical journals; The Lancet.
  • ULORIC® (TMX-67, febuxostat) Receives FDA Approval forthe Chronic Management of Hyperuricemia in Patients with Gout February 14, 2009
  • Tokyo and Osaka, Japan, February 14, 2009 – Teijin Pharma Limited (Head office: Chiyoda-ku, Tokyo; President: Osamu Nishikawa, hereafter “Teijin Pharma”) and Takeda Pharmaceutical Company Limited (Head office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, hereafter “Takeda”) announced today that on February 13, 2009, Teijin Pharma’s U.S. licensee for febuxostat and Takeda’s wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., (Head office: Deerfield, Illinois) received FDA marketing approval for ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout. Takeda Pharmaceuticals North America is the sole developer and marketer of the product, ULORIC in the U.S.
  • FY2008 Development Pipeline Update D R A p p p and R&D Activities Masato Iwasaki General Manager Strategic Product Planning Dept. M P A P Recent Pipeline Progress Development Code Indication (Region) Ph I Ph II Ph III NDA Approval AD-4833 Concomitant therapy with insulin (Japan) KAD-1229 Concomitant therapy with Thiazolidinediones (Japan) Fi d d bi ti ith A l di i TCV-116 Fixed-dose combination with Amlodipine Besylate (Japan) TAK-491 Fixed-dose combination with Chlorthalidone (US) MLN8237 Aggressive non-Hodgkin's lymphoma (NHL) and others (US, EU) TAK-701 Advanced malignancies (--) TAK-901 Advanced malignancies (--) MLN9708 Advanced malignancies (--) 1 TAK-937 Acute stroke (--) TMX-67 Hyperuricemia in patients with gout (US) AG-1749 Prevention of Onset of low dose aspirin related gastric ulcer (Japan) AG-1749 Treatment of secondary eradication of Helicobacter pylori (Single pack of three drugs) (Japan) Recent Pipeline Progress TMX-67(ULORIC) This drug is a novel xanthine oxidase inhibitor which was the firs

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top